Diabetes and bone health

被引：49

作者：

Antonopoulou, Marianna ^{[1
]}

Bahtiyar, Guel ^{[1
,2
]}

Banerji, Mary Ann ^{[1
]}

Sacerdote, Alan S. ^{[1
,2
]}

机构：

[1] Suny Downstate Med Ctr, Brooklyn, NY 11203 USA

[2] NYU, Sch Med, Woodhull Med Ctr, Brooklyn, NY 11206 USA

来源：

MATURITAS | 2013年 / 76卷 / 03期

关键词：

Diabetes; Osteoporosis; Fractures; Thiazolidinediones; GROWTH-FACTOR-I; END-PRODUCTS AGES; MINERAL DENSITY; POSTMENOPAUSAL WOMEN; FRACTURE RISK; GLYCEMIC CONTROL; HIP FRACTURE; VERTEBRAL FRACTURES; OLDER WOMEN; MELLITUS;

D O I：

10.1016/j.maturitas.2013.04.004

中图分类号：

R592 [老年病学]; C [社会科学总论];

学科分类号：

030301 [社会学]; 100201 [内科学];

摘要：

The increasing prevalence of diabetes especially type 2 diabetes worldwide is indisputable. Diabetics suffer increased morbidity and mortality, compared to their non-diabetic counterparts, not only because of vascular complications, but also because of an increased fracture incidence. Both types 1 and 2 diabetes and some medications used to treat it are associated with osteoporotic fractures. The responsible mechanisms remain incompletely elucidated. In this review, we evaluate the role of glycemic control in bone health, and the effect of anti-diabetic medications such as thiazolidinediones, sulfonylureas, DPP-4 inhibitors, and GLP-1 agonists. In addition, we examine the possible role of insulin and metformin as anabolic agents for bone. Lastly, we identify the current and future screening tools that help evaluate bone health in diabetics and their limitations. In this way we can offer individualized treatment, to the at-risk diabetic population. (C) 2013 Elsevier Ireland Ltd. All rights reserved.

引用

页码：253 / 259

页数：7

共 70 条

[1]

Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation [J].